FSD Pharma Inc. mentioned in the Forbes article
October 6, 2022

The founder and MD of Wilson Worldwide, Josh Wilson, published an article on Forbes titled, "Documentary ‘After The Roar’ Looks At Men's Mental Health Post Sports Retirement". The ‘After The Roar’ documentary looks at the mental health struggles former elite sportsmen face after they retire.

Zeeshan Saeed, President and Co-Founder of FSD Pharma, was interviewed for Mr. Wilson’s article to provide unique insight on the subject that is integral to FSD Pharma’s mission to develop novel molecules for “Total Brain Health” for millions of people suffering worldwide today. Mr. Wilson quoted Zeeshan saying, “Mental health is a vital element in everything that we do at FSD. There is a big issue with mental health that has been recognized more and more in recent years, unfortunately sometimes through tragic stories. A documentary explaining the feelings and scenarios for an audience is deeply important.” Zeeshan further opined, “Sometimes these issues cause chemical imbalances that can be solved acutely through drugs and therapy or one or the other. Ultimately, the most important thing is that we recognize that this is an issue, and we should - as a society - be focused on fixing it. It’s not just athletes. This is a widespread issue that many in the scientific community are trying to tackle. It also affects military members that similarly, are trained mentally and physically, but not emotionally to deal with the ceasing of action post-combat.”

To read the full article, please visit: https://www.forbes.com/sites/joshwilson/2022/09/27/documentary-after-the-roar-looks-at-mens-mental-health-post-sports-retirement

Receive most valuable updates straight into your inbox

SIGN UP TODAY



PLEASE SEND INVESTOR INQUIRIES TO [email protected]

ALL OTHER INQUIRIES PLEASE EMAIL [email protected]

JOIN OUR TEAM

Careers

    Email Alerts

    Please fill out the form below to receive company press releases via email when they occur.


    Contact




      PLEASE SEND INVESTOR INQUIRIES TO [email protected]


      ALL OTHER INQUIRIES PLEASE EMAIL TO [email protected]




      TOP